Sector ownership intelligence

Healthcare insider conviction

Executive and director activity assessed across 523 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardCompany signalsFiling ledgerData API
42/100

Distribution bias

94/100 confidence
Level
Sector
Evidence window
Latest 90 days
Named insiders
2761
Latest evidence
11 Sep 2026

Capital positioning read

Distribution bias

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Demand a stronger confirmation bar

Evidence in favour

  • 1126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 2761 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 11 Sep 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction42Distribution bias
Confidence94Deep evidence
Controlled events5345directional common-share events
Company breadth523represented companies
Acquisition value$718.6Mnormalized amount
Disposal value$7.6Bnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

122329 Jun
61006 Jul
93513 Jul
33720 Jul
64327 Jul
83403 Aug
106410 Aug
91717 Aug
56824 Aug
107531 Aug
32807 Sep
014 Sep
AcquisitionsDisposalsScore 42 · Confidence 94

Relative positioning

Sector peer map

Current score with confidence.

FinancialsConviction accumulation7675 confidence Real EstateConviction accumulation6993 confidence UtilitiesAccumulation bias6396 confidence Basic MaterialsAccumulation bias5995 confidence Financial ServicesBalanced insider tape5195 confidence Consumer DefensiveBalanced insider tape4994 confidence EnergyBalanced insider tape4794 confidence IndustrialsBalanced insider tape4694 confidence Consumer CyclicalBalanced insider tape4494 confidence HealthcareDistribution bias4095 confidence Communication ServicesDistribution bias3392 confidence TechnologyConcentrated distribution2695 confidence

Directional balance

Controlled event mix

21.1%acquisition
Acquisition events
1126
Disposal events
4219
Net value
-$6.9B

Industry architecture

Healthcare conviction by industry

Activity and normalized value are shown alongside the controlled group read.

Biotechnology256 companies38%acquisition filings · net $-3.7BDrug Manufacturers - Specialty & Generic43 companies29%acquisition filings · net $-507.1MMedical Devices78 companies47%acquisition filings · net $-382.6MDiagnostics & Research29 companies24%acquisition filings · net $-901.3MHealth Information Services26 companies39%acquisition filings · net $-45.9MMedical Instruments & Supplies34 companies53%acquisition filings · net $-53.1MMedical Care Facilities29 companies38%acquisition filings · net $-968.8MDrug Manufacturers - General12 companies44%acquisition filings · net $-92.8MHealthcare Plans11 companies45%acquisition filings · net $-151.8MMedical Distribution4 companies41%acquisition filings · net $-119.4MPharmaceutical Retailers1 companies100%acquisition filings · net $0

Evidence quality

What the filings represent

Common equity6932
Equity compensation1092
Options and derivatives1836
Other securities122

Decision makers

Role participation

Director3260
Other executive2649
CEO and chair2148
Finance leadership878
Other or unspecified690
Large holder357

Quality controls

Evidence usability

Normalized values
58%
Priced common share
55%
Named insiders
2761
Controlled events
5345

Auditable evidence

Latest Healthcare filings

Showing 1 to 30 of 9982.

EWEdwards Lifesciences Corp
LIPPIS, DANIEL J.CVP, TAVR
DisposalOptions and derivatives
Not reportedContext evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$5.9MDirectional evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$5.2MDirectional evidence
ALHCAlignment Healthcare LLC
KAO, JOHN EDirector, Chief Executive Officer
DisposalCommon equity
$4.9MDirectional evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$3.5MDirectional evidence
HALOHalozyme Therapeutics Inc
TORLEY, HELENDirector, PRESIDENT AND CEO
DisposalCommon equity
$1.7MDirectional evidence
ALHCAlignment Healthcare LLC
MARONEY, DAWN CHRISTINEPresident
DisposalCommon equity
$1.6MDirectional evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$1.2MDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$837.3KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$652.2KDirectional evidence
CADLCandel Therapeutics Inc
TAK, PAUL PETERDirector, Chief Executive Officer
DisposalCommon equity
$620.9KDirectional evidence
HALOHalozyme Therapeutics Inc
TORLEY, HELENDirector, PRESIDENT AND CEO
DisposalCommon equity
$484.8KDirectional evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$428.5KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$414.6KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$371.4KDirectional evidence
HALOHalozyme Therapeutics Inc
TORLEY, HELENDirector, PRESIDENT AND CEO
DisposalOptions and derivatives
$368.2KContext evidence
HALOHalozyme Therapeutics Inc
TORLEY, HELENDirector, PRESIDENT AND CEO
AcquisitionCommon equity
$368.2KDirectional evidence
NTRANatera Inc
RABINOWITZ, MATTHEWDirector, EXECUTIVE CHAIRMAN
DisposalCommon equity
$260.0KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$199.3KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$116.8KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$86.0KDirectional evidence
CYTKCytokinetics Inc
LANDRY, ROBERT EDirector
DisposalCommon equity
$74.7KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$65.6KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$56.6KDirectional evidence
EWEdwards Lifesciences Corp
LIPPIS, DANIEL J.CVP, TAVR
DisposalCommon equity
$54.2KDirectional evidence
EWEdwards Lifesciences Corp
LIPPIS, DANIEL J.CVP, TAVR
AcquisitionCommon equity
$45.0KDirectional evidence
EWEdwards Lifesciences Corp
CHOPRA, DAVEENCVP, TMTT, Surgical & IHFM
DisposalCommon equity
$34.5KDirectional evidence
MDGLMadrigal Pharmaceuticals Inc
SIBOLD, WILLIAM JOHNDirector, President and CEO
DisposalCommon equity
$32.0KDirectional evidence
ISRGIntuitive Surgical Inc
BROSIUS, MARKEVP & Chief Mfg and Supply Cha
DisposalCommon equity
$9.1KDirectional evidence
AVTXAvalo Therapeutics Inc
SULLIVAN, CHRISTOPHER RYANChief Financial Officer
DisposalOptions and derivatives
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context